View ValuationCVS Group 향후 성장Future 기준 점검 3/6CVS Group (는) 각각 연간 21% 및 4.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 22.6% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14.5% 로 예상됩니다.핵심 정보21.0%이익 성장률22.58%EPS 성장률Healthcare 이익 성장18.4%매출 성장률4.6%향후 자기자본이익률14.52%애널리스트 커버리지Good마지막 업데이트11 May 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.공시 • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.공시 • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.공시 • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.공시 • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026공시 • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.공시 • Oct 08+ 1 more updateCVS Group plc Recommends Final Dividend for the Year 2025, Payable on 5 December 2025The Board of CVS Group plc recommends the payment of a final dividend of 8.5p per Ordinary share (2024: 8.0p), subject to shareholder approval at the Annual General Meeting to be held on 18 November 2025. The ex-dividend date is 6 November 2025, the record date is 7 November 2025 and the dividend payment date is 5 December 2025.공시 • May 20Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks. Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction.공시 • Apr 25Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks.공시 • Nov 20CVS Group plc Proposes Final Dividend, Payable on 29 November 2024Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024.공시 • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025공시 • Jun 19CVS Group plc Announces Resignation of Ben Jacklin as Executive DirectorCVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group.공시 • May 01CVS Group plc Announces Board ChangesCVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee.공시 • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024공시 • Oct 27CVS Announce Director ChangesCVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor.공시 • Sep 21CVS Group plc Recommends Final Dividend, Payable on 8 December 2023CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.공시 • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023이익 및 매출 성장 예측OTCPK:CVSG.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수6/30/2028786527911386/30/2027749466310296/30/2026715395093812/31/2025693174782N/A9/30/2025683184882N/A6/30/2025673194882N/A12/31/2024656172467N/A9/30/2024647212467N/A6/30/2024639252568N/A12/31/2023613454689N/A9/30/2023601474287N/A6/30/2023589483985N/A3/31/2023593364383N/A12/31/2022577294881N/A9/30/2022566284978N/A6/30/2022554265176N/A3/31/2022546263961N/A12/31/2021538262647N/A9/30/2021524223554N/A6/30/2021510194460N/A3/31/2021480156276N/A12/31/2020449118092N/A9/30/202043897385N/A6/30/202042866578N/A3/31/202043295366N/A12/31/2019436134155N/A9/30/201942111N/A48N/A6/30/20194078N/A41N/A3/31/20193867N/A36N/A12/31/20183657N/A31N/A9/30/20183469N/A34N/A6/30/201832711N/A37N/A3/31/201831410N/A37N/A12/31/201730010N/A36N/A9/30/201728611N/A33N/A6/30/201727212N/A30N/A3/31/201725911N/AN/AN/A12/31/201624710N/A29N/A9/30/20162328N/A28N/A6/30/20162187N/A28N/A3/31/20162027N/AN/AN/A12/31/20151866N/A22N/A9/30/20151776N/A20N/A6/30/20151677N/A19N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: CVSG.F 의 연간 예상 수익 증가율(21%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: CVSG.F 의 연간 수익(21%)이 US 시장(16.8%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: CVSG.F 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.수익 대 시장: CVSG.F 의 수익(연간 4.6%)이 US 시장(연간 11.7%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: CVSG.F 의 수익(연간 4.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: CVSG.F의 자본 수익률은 3년 후 14.5%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/23 04:16종가2026/04/17 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스CVS Group plc는 13명의 분석가가 다루고 있습니다. 이 중 9명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Sharanya GajapathyBarclaysJames BaylissBerenbergAllan SmylieDavy10명의 분석가 더 보기
공시 • May 14Converium Capital Sends Letter to CVS GroupOn May 13, 2026, Converium Capital Inc. announced that it has sent a letter to CVS Group Plc's Board of Directors highlighting the Company's undervaluation and urging the immediate initiation of a £100 million share buyback, equivalent to 12.5% of the Company's current market capitalization. In addition, Converium says a buyback is the highest-return use of capital currently available, the Company has capacity to fund it, and Converium stating that it remains available to discuss, and it is continuing its dialogue with other shareholders in the meantime.
공시 • Apr 23Cvs Group plc Announces Appointment of Laura Hagan as Independent Non-Executive Director, Effective May 1, 2026CVS Group plc announced the appointment of Laura Hagan as an Independent Non-Executive Director with effect from May 1, 2026. Laura is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at FeverTree Drinks plc and was, until March 2026, Chief People Officer at Deliveroo plc. Laura's earlier executive roles include Chief People Officer at Gymshark Ltd, Chief HR Officer at Tate & Lyle plc and Group HR Director at Dyson Ltd. Laura has a wealth of experience in people leadership, organisation design optimisation, international expansion and the delivery of customer driven service through technology. Laura's blend of experience operating in both FTSE 250 and fast growth privately owned companies will add value to the board. From the date of her appointment, Laura will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. Laura's appointment, following that of Helen Keays and Jane Bednall announced on March 25, 2026, adds complementary skills and experience to the Board through her extensive listed company experience and her expertise in people development, leadership, customer service and international expansion.
공시 • Mar 30+ 1 more updateCVS Group plc Announces Retirement of CEO Richard FairmanCVS Group plc announced that Richard Fairman has informed the Board of his intention to retire from his role as Chief Executive Officer for personal reasons. Richard will remain in post until a successor is appointed, to ensure an orderly transition, and he will continue to drive the business forward in the meantime. Since joining CVS in 2018 as CFO and assuming the role of CEO in 2019, Richard has led the Group through a period of significant strategic progress in support of its purpose to provide the best possible care to animals. Under Richard's leadership, CVS has built a culture centered on clinical excellence, strengthened its position as veterinary employer of choice and delivered sustainable growth alongside successful international expansion into the Australian market. During Richard's tenure, the Group has grown to approximately 9,000 employees including approximately 2,500 vets and 3,300 veterinary nurses and patient care assistants across approximately 475 practices and EBITDA has nearly tripled. Richard also guided the business through to the conclusion of the CMA process and, during the same period, oversaw the Group's step-up to the Main Market of the London Stock Exchange and its subsequent inclusion into the FTSE 250 index.
공시 • Mar 25CVS Group plc Announces Board and Committee ChangesCVS Group plc announced the appointment of Helen Keays and Jane Bednall as Independent Non-Executive Directors with effect from 1 April 2026, the retirement of Deborah Kemp with effect from 30 June 2026 and a change in Chair of the Group's Nomination Committee. Deborah Kemp, who joined the board in January 2018 and who is presently Senior Independent Director and Chair of the Remuneration Committee will retire and step down from the Board and all board committees on 30 June 2026. Helen Keays is presently an Independent Non-Executive Director and Chair of the Remuneration Committee at Nichols plc following an executive career in consumer-facing multi-site businesses across retail, mobile telecommunications and retail financial services. Helen has worked at Vodafone plc, latterly as General Manager of Singlepoint, and previously at Sears plc. Helen has previously been an Independent Non-Executive Director of The Restaurant Group, Domino's Pizza UK & Ireland, Communisis plc, Majestic Wine plc, Mattioli Woods plc and Chrysalis Group plc. Helen is an experienced Non-Executive Director and Remuneration Committee Chair and will add value to the board through her expertise in people development, consumer marketing and CRM. From the date of her appointment, Helen Keays will become Chair Designate of the Remuneration Committee and will also become a member of the Group's Audit and Risk Committee and Nomination Committee. Helen will formally become Chair of the Remuneration Committee with effect from 1 July 2026. Jane Bednall is presently an Independent Non-Executive Director of Fuller Smith & Turner plc and Independent Non-Executive Director and Chair of the Remuneration, People and Culture Committee for The Kings Cross Group, appointed on behalf of AustralianSuper, Australia's largest pension fund. This follows an executive career in senior leadership roles at British Airways, InterContinental Hotel Group (IHG), Centrica and most recently SSE plc where she was Chief Marketing Officer and formerly Managing Director of Retail Energy. Jane was previously Non-Executive Director of DFS plc, EI Group plc and Smart Energy GB. Jane will add value to the board through her experience in multi-site retail and leisure businesses and her expertise in branding, consumer behaviour and insights. From the date of her appointment, Jane will become a member of the Group's Remuneration Committee, Audit and Risk Committee and Nomination Committee. David Wilton, Chair of CVS, will succeed Richard Gray as Chair of the Nominations Committee with effect from 1 April 2026.
공시 • Nov 14+ 1 more updateCVS Group plc to Report First Half, 2026 Results on Feb 26, 2026CVS Group plc announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Oct 24CVS Group plc (AIM:CVSG) announces an Equity Buyback for £20 million worth of its shares.CVS Group plc (AIM:CVSG) announces an share repurchase program. Under the program, the company will repurchases up to £20 million. The purpose of the Share Buyback Program is to both return surplus capital to shareholders and reduce the Group's share capital pursuant to its capital allocation policy. As such, all Ordinary Shares repurchased by the Group under the Share Buyback Program will be cancelled. The program will valid till Q1 of calendar year 2026.
공시 • Oct 08+ 1 more updateCVS Group plc Recommends Final Dividend for the Year 2025, Payable on 5 December 2025The Board of CVS Group plc recommends the payment of a final dividend of 8.5p per Ordinary share (2024: 8.0p), subject to shareholder approval at the Annual General Meeting to be held on 18 November 2025. The ex-dividend date is 6 November 2025, the record date is 7 November 2025 and the dividend payment date is 5 December 2025.
공시 • May 20Anima Care UK Limited acquired Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks. Anima Care UK Limited completed the acquisition of Crematoria operations of CVS Group plc (AIM:CVSG) on May 19, 2025. In related transaction, CVS Group plc completed the acquisition of VPP Group. Christopher Golden, James Steel and Andrew Clark of Peel Hunt LLP acted as financial advisor for CVS Group plc. Toby Flaux, Michael Burke, James Thompson and Milo Bonser brokered the transaction.
공시 • Apr 25Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million.Anima Care UK Limited agreed to acquire Crematoria operations of CVS Group plc (AIM:CVSG) for £42.4 million on April 24, 2025. A cash consideration of £42.4 million will be paid by Anima Care UK Limited. As part of consideration, £42.4 million is paid towards assets of Crematoria operations of CVS Group plc. As part of the acquisition, Funecap will provide clinical waste disposal and cremation services to CVS practices and clients following completion. The capital generated from the divestment provides additional firepower for continued selective investment in the UK and expansion in Australia. The capital recycling is expected to be value accretive to the Group in due course and allows CVS to focus on its core veterinary and diagnostics services. For the period ending December 31, 2024, Crematoria operations of CVS Group plc reported total revenue of £12 million and EBITDA of £4.3 million. As of December 31, 2024, Crematoria operations of CVS Group plc reported total common equity of £23.6 million. The expected completion date of the transaction is within the next five weeks.
공시 • Nov 20CVS Group plc Proposes Final Dividend, Payable on 29 November 2024Subject to shareholder approval at the AGM, CVS Group plc intends to pay its previously announced final dividend of 8.0 pence per ordinary share on 29 November 2024 to holders on the register as at 1 November 2024. The ex-dividend date was 31 October 2024.
공시 • Nov 16+ 1 more updateCVS Group plc to Report Fiscal Year 2025 Results on Sep 25, 2025CVS Group plc announced that they will report fiscal year 2025 results on Sep 25, 2025
공시 • Jun 19CVS Group plc Announces Resignation of Ben Jacklin as Executive DirectorCVS Group plc announces that Ben Jacklin, Executive Director, has resigned. Ben's managerial and operational responsibilities, including the provision of clinical guidance to the Board, have been assumed by other senior members of the Group.
공시 • May 01CVS Group plc Announces Board ChangesCVS Group plc announced the appointment of David Wilton as Chair with effect from 1 May 2024. David has served as an Independent Non-executive Director of the Company since September 2021. David is a qualified Chartered Accountant with more than 30 years' post-qualification experience as a Chief Financial Officer, Non-Executive Director (NED), Chair and consultant after many years in corporate finance, primarily in mid-cap M&A with Rothschilds. David has held roles in both public and private-equity backed companies including as CFO of Sumo Group plc, Group Finance Director of WYG plc and NED and Chair of the Audit Committee of Sweett Group plc. David was NED and subsequently Chair at Frontier Developments plc until November 2023. David is currently also NED and Chair Designate at Gateley (Holdings) plc. He has extensive experience of people businesses and of regulatory processes. David also brings to the Chair role a significant amount of technical expertise, which will support CVS in its strategic delivery of investment in technology. David Wilton's appointment follows a comprehensive search by the Nomination Committee, supported by a blue chip recruitment firm who sourced a number of high quality candidates. The Board would like to thank Deborah Kemp, the Group's Senior Independent Director who has been acting as Interim Chair during the search period. David will remain as Audit Committee Chair until this process is completed, at which point he will then step down as a member of the Audit Committee.
공시 • Dec 13+ 2 more updatesCVS Group plc to Report First Half, 2024 Results on Feb 29, 2024CVS Group plc announced that they will report first half, 2024 results on Feb 29, 2024
공시 • Oct 27CVS Announce Director ChangesCVS announced that its Chair Richard Connell has taken the difficult decision to resign with immediate effect due to ill health. Deborah Kemp, the Group's Senior Independent Director will assume the role of Chair for the interim period whilst the Board commences a process to appoint a permanent successor.
공시 • Sep 21CVS Group plc Recommends Final Dividend, Payable on 8 December 2023CVS Group plc recommends continuation of progressive dividend policy, with the payment of a final dividend of 7.5 pence per Ordinary share (2022: 7.0 pence). The ex-dividend date is 2 November 2023 and the dividend payment date is 8 December 2023.
공시 • Nov 12+ 2 more updatesCVS Group plc to Report Q4, 2023 Results on Sep 21, 2023CVS Group plc announced that they will report Q4, 2023 results on Sep 21, 2023